Unraveling Mitochondrial Determinants of Tumor Response to Radiation Therapy

Int J Mol Sci. 2022 Sep 26;23(19):11343. doi: 10.3390/ijms231911343.

Abstract

Radiotherapy represents a highly targeted and efficient treatment choice in many cancer types, both with curative and palliative intents. Nevertheless, radioresistance, consisting in the adaptive response of the tumor to radiation-induced damage, represents a major clinical problem. A growing body of the literature suggests that mechanisms related to mitochondrial changes and metabolic remodeling might play a major role in radioresistance development. In this work, the main contributors to the acquired cellular radioresistance and their relation with mitochondrial changes in terms of reactive oxygen species, hypoxia, and epigenetic alterations have been discussed. We focused on recent findings pointing to a major role of mitochondria in response to radiotherapy, along with their implication in the mechanisms underlying radioresistance and radiosensitivity, and briefly summarized some of the recently proposed mitochondria-targeting strategies to overcome the radioresistant phenotype in cancer.

Keywords: ROS; mitochondria; mitochondria-targeting compounds; radioresistance; radiotherapy; tumor hypoxia.

Publication types

  • Review

MeSH terms

  • Cell Line, Tumor
  • Humans
  • Hypoxia / metabolism
  • Mitochondria / metabolism
  • Neoplasms* / genetics
  • Neoplasms* / metabolism
  • Neoplasms* / radiotherapy
  • Radiation Tolerance / genetics
  • Reactive Oxygen Species / metabolism

Substances

  • Reactive Oxygen Species

Grants and funding

This research received no external funding.